View clinical trials related to Stroke.
Filter by:The goal of this clinical trial is to investigate the feasibility of the application of robot mediated impairment-training (RMIT) and robot mediated task-specific training (RMTT) in acute stroke patients with upper limb impairments. The main question[s] it aims to answer are: - Is it feasible and safe to conduct RMIT and RMTT in acute stroke patients with upper limb impairments? - What are the preliminary effects on the physical function and quality of life in these patients? Participants will undergo 20 hours of robot mediated upper limb therapy. Researchers will compare RMIT with RMIT+RMTT to see if there are any differences in the effects on physical function and quality of life.
About half of the patients with acute ischemic stroke treated with endovascular thrombectomy (EVT) remain dependent on the help of others or die in the first 90 days. We hypothesize that treatment with ghrelin, started in the first six hours after stroke onset, improves early recovery and long-term functional outcome in these patients. Ghrelin is a naturally occurring hormone and mildly excitatory neurotransmitter also known as the 'hunger hormone.' Treatment with acylated ghrelin consistently improved functional and histological recovery in in vitro and in vivo models of ischemic stroke.
Patients with atrial fibrillation (AF) who have had a prior stroke are at very high risk of recurrent ischemic stroke. About 40% of these strokes are due to large emboli which result in large cerebral vessel occlusion (LVO). This randomized control trial aims to address this unmet need by testing whether use of bilateral carotid filter implants in addition to OAC will reduce the risk of stroke in AF patients with recent (e.g. within 12 months) ischemic stroke vs. only OAC.
The goal of this clinical trial is to compare the use of long-term vs. shorter-term heart monitoring to detect atrial fibrillation after stroke. Patients will be implanted with a loop recorder and will have study follow-up at 3-, 6- an 12-months after implantation. The investigators will evaluate 24 patients, between the 3 centers, in the same way the investigators plan to evaluate a larger number of participants (>1000) in a future study. This will allow us to learn if such a study is possible, identify potential implementation challenges, and develop strategies to overcome those difficulties.
This is a forward-looking, open, one-arm, and real clinical trial world. The researchers plan to recruit at least 50 qualified patients. The main purpose of this study is to establish a population pharmacokinetic model of ticagrelor , explore the correlation between its blood concentration and the events of ischemia and the adverse effects of hemorrhage, and evaluate the effectiveness and safety of ticagrelor in the treatment of ischemic cerebrovascular disease.
The goal of this clinical trial is to evaluate the effectiveness of an immersive virtual-reality (IVR) based stimulation program, in improving visual perception for people who have lost their driver's license due to perceptual or cognitive impairments. The main questions it aims to answer are: 1. Can the 6-week IVR stimulation program help improve driving performance? 2. Will participants experience improvement in visual detection and perception after training? Study Design Summary: - Participants will be randomized into a waitlist group or intervention-first group - The VR-based intervention will consist of training every 2 days for six weeks - Waitlist group will wait 6 weeks before starting intervention at study midpoint (week 7) - Intervention-first group will begin with intervention (week 1-6) and then stop intervention at study midpoint - Participants will complete tests related to driving performance, visual attention, and visual fields at the start of study, midpoint, and end of study Researchers will analyze data for changes from baseline in outcome measures.
The primary goal of the clinical trial is to test the effect of oral rivaroxaban plus aspirin in patients with recent stroke/ transient ischemic attack (TIA) caused by intracranial artery stenosis. Participants will be divided into 2 groups to receive either oral rivaroxaban plus aspirin or oral clopidogrel plus aspirin. The main question it aims to answer is whether the experimental group (oral rivaroxaban plus aspirin) is superior to the control group ( oral clopidogrel plus aspirin) to lower recurrent stroke/TIA or death in these patients during 1 year of follow-up.
To evaluate the safety and tolerability of IxCellhUC-MSC-S as a single intravenous infusion in convalescent patients with ischemic stroke. To explore the efficacy of IxCellhUC-MSC-S as a single intravenous infusion in patients with convalescent ischemic stroke.
The goal of this clinical trial is to evaluate the effect of evolocumab in combination with statin therapy (atorvastatin) in acute ischemic stroke (AIS).
From the region around Brussels there are currently few data on how the post-stroke process take place and how satisfied the care providers are with it. For this reason, this survey is set up with the aim of examining four pillars: the epidemiology of stroke, communication between neurologists and GPs and satisfaction with it, secondary prevention of cardiovascular disease and control/treatment of the most common sequelae after stroke. In the latter two, the emphasis is on detection and treatment, and explicitly on whose task this is (neurologist versus GP), with the aim of verifying the mutual consensus on treatment and the subsequent detection of treatment shortcomings. This study will mainly consist of interviewing general practitioners and neurologists in the periphery of Brussels. This will be done by means of partly structured questionnaires, that will be send out to the medical professionals by contact with the central umbrella organisations of neurology in the hospitals and contact with the various general practitioners' practices (directly or through the multidisciplinary meetings per region). The questionnaires will be made up in google forms, as this programme allows efficient data processing, is eas-ily understandable for every participant and as no individual patient data will be processed.